Scarica l'app Stockscreener
0.00
100.00%
-12.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.58
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$718.13M
Reddito:
-
Utile/perdita netta:
$-72.89M
Rapporto P/E:
0.00
EPS:
-2.42
Flusso di cassa netto:
$-68.47M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$13.29
Astria Therapeutics Inc Stock (ATXS) Company Profile
Nome
Astria Therapeutics Inc
Settore
Industria
Telefono
617-349-1971
Indirizzo
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
0.00 | 718.13M | 0 | -72.89M | -68.47M | -2.42 |
VRTX
Vertex Pharmaceuticals Inc
|
427.34 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.21 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.17 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.30 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-29 | Iniziato | TD Cowen | Buy |
| 2023-03-28 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
Ikena Oncology stock (US4517401090): takeover by Astria Therapeutics reshapes the story - AD HOC NEWS
BioCryst Maintains 2026 ORLADEYO Revenue Guidance Amid Growth - HarianBasis.co
BioCryst (NASDAQ: BCRX) takes $697.8M navenibart R&D hit after Astria deal - Stock Titan
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
BioCryst To Acquire Astria Therapeutics In $700M Deal - MSN
Cantor Fitzgerald Downgrades Astria Therapeutics (ATXS) - MSN
HC Wainwright & Co. Downgrades Astria Therapeutics (ATXS) - MSN
Street Watch: Whats the MACD signal for Astria Therapeutics IncEntry Point & Reliable Price Breakout Alerts - baoquankhu1.vn
Whale Trades: Is Astria Therapeutics Inc trading at a discount2026 Year in Review & Verified Technical Signals - baoquankhu1.vn
Aug Momentum: Is Astria Therapeutics Inc stock forming a cup and handle2026 EndofYear Setup & Expert Curated Trade Setups - baoquankhu1.vn
Published on: 2026-04-08 03:02:22 - baoquankhu1.vn
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer - Yahoo Finance
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets - Yahoo Finance
Meme Stocks: Can Astria Therapeutics Inc ride the EV wave2026 PostEarnings & Accurate Intraday Trade Tips - baoquankhu1.vn
Can Astria Therapeutics Inc reach all time highs this yearQuarterly Portfolio Review & Low Risk Entry Point Guides - baoquankhu1.vn
Astria Therapeutics (ATXS) price target decreased by 17.94% to 21.62 - MSN
Performance Recap: Should I invest in Astria Therapeutics Inc before earningsQuarterly Portfolio Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trend Report: Whats the fair value of Astria Therapeutics Inc stock2026 Big Picture & Real-Time Buy Signal Alerts - baoquankhu1.vn
BioCryst Pharmaceuticals Sees Profitable Quarter Amid Strategic Moves - StocksToTrade
BioCryst Stock Surges After Strong Q4 Earnings and Astria Acquisition - timothysykes.com
ATXS SEC FilingsAstria Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush - Yahoo Finance
Analyst Upgrade: Can Astria Therapeutics Inc stock outperform in a bear marketInsider Buying & AI Forecasted Stock Moves - baoquankhu1.vn
Risks Report: Whats the fair value of Astria Therapeutics Inc stockJuly 2025 Pullbacks & Verified Entry Point Signals - baoquankhu1.vn
Moving Averages: What hedge funds are buying Astria Therapeutics IncAnalyst Upgrade & Growth Focused Stock Pick Reports - baoquankhu1.vn
Evercore ISI sees long-term growth potential for BioCryst Pharmaceuticals, Inc. (BCRX) following Astria acquisition - MSN
Less bullish OX40 field as Kyowa bid plowed under - BioWorld News
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio - Yahoo Finance
BioCryst’s First Profitable Year Recasts Hereditary Angioedema Growth Story - Yahoo Finance
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Finviz
BCRX: $400M Blackstone term loan funds Astria deal, secured by assets, matures 2031, SOFR+4.5% - TradingView
BioCryst (BCRX) Achieves Record Revenue and Profitability Milest - GuruFocus
BioCryst (NASDAQ: BCRX) posts 2025 profit, keeps 2026 revenue outlook - Stock Titan
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Rare-disease drugmaker BioCryst turns first annual profit, wins FDA OK for kids - Stock Titan
BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed? - Yahoo Finance
ATXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Spikes: Can Astria Therapeutics Inc ride the EV waveQuarterly Earnings Report & Community Verified Trade Signals - baoquankhu1.vn
Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition - Insider Monkey
What are the future prospects of Astria Therapeutics Inc.2025 EndofYear Setup & Weekly High Potential Stock Alerts - mfd.ru
Can Astria Therapeutics Inc. ride the EV wave2025 Earnings Surprises & Technical Analysis for Trade Confirmation - mfd.ru
Is Astria Therapeutics Inc.’s ROE strong enoughTrade Volume Summary & Weekly Sector Rotation Insights - mfd.ru
BioCryst (BCRX) Poised for Growth with Key Acquisition and Positive Outlook - GuruFocus
Former 5% holder Vestal Point reports 0% stake in Astria (ATXS) - Stock Titan
Glazer Capital reveals 6.61% Astria Therapeutics (ATXS) stake in 13G/A - Stock Titan
Can Astria Therapeutics Inc. maintain its current growth rateJuly 2025 Trends & Capital Efficiency Focused Strategies - mfd.ru
Analyst Calls: Should I invest in Astria Therapeutics Inc before earnings2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Perceptive reports 0% stake in Astria Therapeutics (ATXS) after BioCryst deal - Stock Titan
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap - Yahoo Finance
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy - MSN
Astria Therapeutics Inc Azioni (ATXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):